ADCT-212 / ADC Therapeutics - LARVOL DELTA

Preclinical development of ADCT-212, a PSMA-targeted antibody-drug conjugate employing the pyrrolobenzodiazepine dimer SG2000 for PSMA-expressing cancers (AACR 2023) - "ADCT-212 was tolerated as a single 20 mg/kg dose in male rats, with exposure data being indicative of a linear PK profile with a half-life of approximately 12 days. In conclusion, ADCT-212 demonstrated potent and specific in vitro and in vivo anti-tumor activity while it was stable and well tolerated in the rat, warranting further development of ADCT-212 into the clinic."

Preclinical • Colon Cancer • Genito-urinary Cancer • Lung Cancer • Oncology • Prostate Cancer • Solid Tumor • FOLH1

ADC Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Updates (Businesswire) - "Upcoming Expected Milestones....ADCT-212 (targeting PSMA): Initiate Phase 1 study in 1H 2024. ADCT-602 (targeting CD22): Complete Phase 1 dose expansion study in 1H 2024. ADCT-701 (targeting DLK-1): Initiate Phase 1 study in 2H 2023."

New P1 trial • Trial status • Oncology

ADC Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Updates (Businesswire) - "ZYNLONTA® (loncastuximab tesirine-lpyl) net sales of $21.3 million in the third quarter of 2022 (+23% vs. 2Q 2022)...ADCT-212 (targeting PSMA)- Progress toward IND filing and initiation of Phase 1 trial in 2023; ADCT-701 (targeting DLK-1)- Progress toward IND filing and initiation of Phase 1 trial in 2023."

IND • Sales • Hematological Malignancies • Oncology • Solid Tumor

ADC Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Updates (Businesswire) - "Upcoming Expected Milestones: ZYNLONTA...Initiate the LOTIS-9 trial of ZYNLONTA + rituximab in 1L unfit/frail DLBCL patients in 2H 2022; Initiate the LOTIS-7 trial of ZYNLONTA in multiple combinations in NHL in 1H 2022; Cami: Report topline results for the Phase 2 trial in HL in 1H 2022; Meet with FDA for pre-BLA meeting in 2H 2022; ADCT-601 (targeting AXL): Initiate the Phase 1b combination study in multiple solid tumors in 1H 2022; ADCT-701 (targeting DLK1): Continue to work with the NCI for completion of preclinical studies to support an IND filing; ADCT-212 (targeting PSMA): Continue completion of preclinical studies to support an IND filing."

IND • New P1 trial • New trial • Preclinical • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Hodgkin Lymphoma • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Solid Tumor